Figure 4
From: Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer
EGFR signalling pathway, including downstream markers and the proposed effects of erlotinib.
Figure 4 | British Journal of Cancer
From: Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer
EGFR signalling pathway, including downstream markers and the proposed effects of erlotinib.
